

CEPI'S MAJOR PROGRAMMATIC ACHIEVEMENTS

2017 to present

ENABLING PROJECTS

Centralised lab network



Established a global network of **19 laboratories** to support priority pathogen vaccine R&D

Preclinical models network



Established a global network of **17 facilities**

Manufacturing network



Established a network of **6 Vaccine Manufacturing Facility partners**

Epidemiology study



Launched ENABLE, the **largest-ever** Lassa epidemiology study

CEPI FIRSTS

Nipah



Advanced the **first ever** Nipah vaccine into **Phase 2** trials

Rift Valley fever



Advanced RVF vaccine into **Phase 2** trials

MERS



Advanced the **first ever** MERS vaccine into **Phase 2** trials

Lassa fever



Advanced the **first ever** Lassa virus vaccine into **Phase 2** trials

Chikungunya



First **licensed** Chikungunya vaccine


Innovations



Supported the **first medical product designed using AI** to be approved for any indication anywhere in the world.

CORONAVIRUSES

COVID-19



Supported **14** COVID-19 vaccine candidates
4 granted EUL
3 approved for domestic use

BPCV



World's leading funder of vaccine R&D, investing in **14** broadly protective coronavirus vaccine candidates

COVAX launched and co-led by CEPI



Nearly **2 billion** vaccines



shipped to **146 countries**



2.7 million deaths averted in lower-income countries

FILOVIRUSES

Ebola



Supported generation of data to support expanded access and licensed vaccines

Marburg

10 DAYS

Supported Rwandan led response which deployed vaccine into a clinical trial